NanoVibronix Inc (NAOV) Actualités

Form DEF 14A - Other definitive proxy statements

Form PRE 14A - Other preliminary proxy statements

Form 8-K - Current report

NanoVibronix Advances Development of PainShield and UroShield with Completion of NextGen Prototypes

Development advancing to verification and testing phase; Aims to future-proof design, lower componentry costs and improve manufacturing...

Form 8-K - Current report

NanoVibronix Announces Completion of Pilot Phase of Clinical Study of UroShield® at the University of Michigan

Research expected to advance to ‘Full Study’ phase in 2025 NanoVibronix, Inc. (NASDAQ: NAOV) (the “Company”), a medical device company that...

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Form 8-K - Current report

Form 8-K - Current report

Form 8-K - Current report

NanoVibronix Secures $12 Million Minimum Purchase Commitment for PainShield with Extension of Distribution Agreement

Extends Relationship with Ultra Pain Products, Inc for Distribution of PainShield for Five Years NanoVibronix, Inc., (NASDAQ: NAOV) (the...

Form 8-K - Current report